← Back to Clinical Trials
Recruiting NCT07512869

NCT07512869 Host Led Harm Reduction Approach Among Men Who Have Sex With Men Who Engaged in Chemsex in Bangkok, Thailand: A Pre-Implementation Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07512869
Status Recruiting
Phase
Sponsor Institute of HIV Research and Innovation Foundation, Thailand
Condition HIV Prevention
Study Type OBSERVATIONAL
Enrollment 76 participants
Start Date 2025-02-17
Primary Completion 2027-02-17

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Self-administered questionnaire assessmentSemi-structured in-depth interviews (IDIs)Development and refinement of harm reduction model

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 76 participants in total. It began in 2025-02-17 with a primary completion date of 2027-02-17.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study evaluates the pre-implementation phase of a host-led harm reduction model for men who have sex with men (MSM) engaging in chemsex in Bangkok, Thailand, focusing on understanding harms, contexts, and needs to develop a tailored intervention.

Eligibility Criteria

Inclusion Criteria: * MSM aged ≥18 years * Able to communicate in Thai * Specific by group: * Chemsex hosts: hosted ≥2 times in past 6 months * Chemsex guests: attended ≥2 times in past 6 months * CSO / hospital / police staff: working ≥3 months in related roles * Provide informed consent Exclusion Criteria: • Unable to provide informed consent (e.g., under substance influence at consent)

Contact & Investigator

Central Contact

Nittaya Phanuphak, MD,PhD.

✉ nittaya.p@ihri.org

📞 6681 825 3544

Principal Investigator

Jakkrapatara Boonruang, MD

PRINCIPAL INVESTIGATOR

Institute of HIV Research and Innovation (IHRI)

Frequently Asked Questions

Who can join the NCT07512869 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying HIV Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07512869 currently recruiting?

Yes, NCT07512869 is actively recruiting participants. Contact the research team at nittaya.p@ihri.org for enrollment information.

Where is the NCT07512869 trial being conducted?

This trial is being conducted at Pathum Wan, Thailand.

Who is sponsoring the NCT07512869 clinical trial?

NCT07512869 is sponsored by Institute of HIV Research and Innovation Foundation, Thailand. The principal investigator is Jakkrapatara Boonruang, MD at Institute of HIV Research and Innovation (IHRI). The trial plans to enroll 76 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology